Castlekeep Investment Advisors LLC Invests $1.76 Million in Cencora, Inc. (NYSE:COR)

Castlekeep Investment Advisors LLC bought a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 7,820 shares of the company's stock, valued at approximately $1,757,000.

A number of other institutional investors and hedge funds also recently modified their holdings of COR. Whittier Trust Co. boosted its stake in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after buying an additional 44 shares in the last quarter. Shepherd Financial Partners LLC lifted its holdings in shares of Cencora by 0.9% in the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after acquiring an additional 46 shares during the last quarter. WASHINGTON TRUST Co boosted its stake in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares in the last quarter. JFS Wealth Advisors LLC raised its position in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. lifted its stake in Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after purchasing an additional 47 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Up 0.3%

Shares of COR traded up $0.87 during mid-day trading on Tuesday, hitting $293.22. 1,241,488 shares of the company's stock traded hands, compared to its average volume of 1,545,066. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $56.83 billion, a P/E ratio of 41.71, a PEG ratio of 1.31 and a beta of 0.60. The business's 50-day moving average price is $283.45 and its 200-day moving average price is $257.75. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the previous year, the firm earned $3.80 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date is Friday, May 16th. Cencora's payout ratio is currently 25.52%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. UBS Group raised their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Citigroup boosted their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Robert W. Baird raised their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and an average target price of $301.18.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. This trade represents a 8.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This trade represents a 9.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,223 shares of company stock worth $12,369,767 over the last three months. Company insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.